Dr. Rebecca Tay Sook Hui
Chief Executive Officer of Beacon Precision Diagnostics
BSc Biomedical Science, MSc Nutrition Physiology, Dual PhD Pharmacy (UPM)(University of Nottingham) & Molecular Medicine
Doctor Rebecca Tay is the CEO of Beacon Precision Diagnostics (BPD), an award-winning, patient-centric, hospital-based pathology and clinical laboratory. Losing her biological mother in her thirties to cancer, Dr. Rebecca has been devoted to becoming a medical scientist for leading-edge medical breakthroughs and healthcare solutions for human diseases. Driven by this devotion, she is grateful to be the first Dual PhD graduate from the University of Nottingham, UK in Pharmacy and University Putra Malaysia (UPM) in Molecular Medicine. She had successfully filed the patent for the discovery of novel molecular pathways associated with clinical outcome improvement. She was overwhelmed by how advancement in Pharmacogenomics (PGx) could potentially integrate into cutting-edge healthcare to prevent adverse drug reactions (ADRs) when she was given an opportunity at The University of Nottingham to teach Pharmacogenomics to the students under the problem-based learning (PBL) program. Geared up with the comprehension of precision medicine, using genetic profiling, she, her husband, and a team of healthcare providers were able to intervene and assist her stepmom in entering remission from her fourth-stage lung cancer. Seeing her stepmom living a quality life in her fifth year since diagnosis, motivated her to develop a cutting-edge diagnostic laboratory that is affordable to the nation.
Teaming up with renowned scientific healthcare policymakers and medical council, she is dedicated to translating scientific discovery into Medical Revolution in the preventative, diagnostic, and therapeutic healthcare industry, transitioning from the ‘One-drug-fits-all” paradigm towards personalized-tailored-treatment, namely Precision Medicine. She managed to acquire millions of investments or sponsorships from various local and Fortune 500 companies and successfully developed genome-wide Pharmacogenomic testing, namely PRECISE Pharmacogenomic. PRECISE Pharmacogenomic reporting is curated with medical databases accredited by UKAS (United Kingdom Accreditation Service) ISO 13485 for the Quality Management System certification NQA (National Quality Assurance Limited) and Health Sciences Authority (HSA), Republic of Singapore to support clinicians for clinical recommendation and personalised targeted treatment.
Under her leadership, BPD has been awarded by The Malaysia Book of Records 2023 for “First Clinical Recommended Genome-wide Pharmacogenomics”, essentially to prevent the top four (CDC, 2021) or top six (Montastruc et al, 2021) leading death from ADR. Additionally, BPD has also successfully curated and validated PRECISE Nutrigenomics focusing on preventive healthcare, facilitating the design of personalized nutrition plans based on an individual’s genetic profile to prevent the onset of diet-related illnesses, reduce obesity, control diabetes, maintain optimal health, and prevent nutrient deficiency.
Dr. Rebecca is currently the principal investigator (PI) of the research collaboration agreement with the National University of Singapore (NUS) on the “Implementation of Pharmacogenomic – A Precision Medicine Initiative”. Together with NUS’s PI, A/Professor Dr Doreen Tan Su-Yin, the agreement aims to oversee and advise on the implementation plan for pharmacogenomics through the design and analysis of surveys and to provide oversight on data analysis and publication. She has been appointed as the Board of Advisory for various universities such as International Medical University (IMU) and University Putra Malaysia (UPM). Committed to Advancing Tomorrow’s Cure, BPD has been invited to sign multiple MOUs with various renowned universities locally and globally that focus on research breakthroughs. Beacon Precision Diagnostics seeks to support our primary care, transforming the first line of defence from sick care to preventive healthcare and reducing the nation’s healthcare economic burden.
Dr. Rebecca has been frequently engaged by various universities, hospitals, corporations, and associations as a guest of honour, keynote speaker, expert opinion forum, judge, and advisor for healthcare, precision medicine, wellness, and entrepreneurship, nationally and globally.